Compare Abbott Laboratories (ABT) vs Lamb Weston Holdings Inc (LW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Lamb Weston Holdings Inc — how do they compare? Abbott Laboratories trades at $95.37 (market cap $166.94B), while Lamb Weston Holdings Inc trades at $46.43 (market cap $6.42B). The key difference: Abbott Laboratories is far larger — about 26× Lamb Weston Holdings Inc's market cap, and Lamb Weston Holdings Inc pays the higher dividend (3.27%). Which is the better fit depends on your goals.
| ABT | LW | |
|---|---|---|
Market Cap | $166.94B | $6.42B |
Sector | Health | Consumer Staples |
52-Week High | $136.62 | $66.57 |
52-Week Low | $82.57 | $38.48 |
Enterprise Value | $193.69B | $10.39B |
Dividend Yield | 2.63% | 3.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Lamb Weston (LW) trades at $46.51, up 1.31% on the day, with a bullish technical signal and consistent earnings beats. The company reported Q1 2026 EPS of $0.72, exceeding the $0.626 estimate, and maintains a P/E of 21.64 and P/S of 0.99. Recent news highlights its 'Focus to Win' strategy driving North America volume gains and cost savings, while activist investors like Starboard Value push for operational improvements.
The outlook is cautiously optimistic, supported by earnings momentum and strategic initiatives, but risks include a class-action lawsuit, margin pressures, and high debt levels. Analyst consensus is mixed with 35% buy ratings, reflecting balanced sentiment amid turnaround efforts and legal overhangs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →
